Human sera from healthy individuals have been shown to react with viral antigens in preparations of de-tergent-disrupted C type viruses from monkeys. In this report, it is demonstrated that (populations of) these human antibodies react with highly purified envelope glycoproteins of the simian sarcoma virus-simian sarcoma-associated virus complex and the Friend leukemia virus complex. Several immunological parameters influencing human antibody binding to C type tumor virus antigens have been characterized. These parameters indicate that human antibodies tend to bind to what is probably a subset of the antigenic determinants on the virus envelope antigens and that different human sera recognize the same antigenic determinants on the virus envelope antigens tested. The possible origin of these antibodies is discussed. Evidence for the presence of oncornavirus particles (1-13) as well as viral antigens (14-20), RNA-dependent DNA polymerase (reverse transcriptase) (21-25), and nucleic acids (22, (26) (27) (28) (29) in normal and malignant human tissues has accumulated steadily over the past few years. Another approach to search for C type virus information in humans is to screen sera from healthy individuals and from patients for antibodies reacting with tumor virus antigens. The presence of such antibodies may indicate previous viral infection.
Human antibodies reactive with purified envelope antigens of primate type C tumor viruses (humoral immunity/oncornaviruses/radioimmunoprecipitation/reaction parameters) REINHARD Communicated by Wolfgang Beermann, August 8, 1978 ABSTRACT Human sera from healthy individuals have been shown to react with viral antigens in preparations of de- tergent-disrupted C type viruses from monkeys. In this report, it is demonstrated that (populations of) these human antibodies react with highly purified envelope glycoproteins of the simian sarcoma virus-simian sarcoma-associated virus complex and the Friend leukemia virus complex. Several immunological parameters influencing human antibody binding to C type tumor virus antigens have been characterized. These parameters indicate that human antibodies tend to bind to what is probably a subset of the antigenic determinants on the virus envelope antigens and that different human sera recognize the same antigenic determinants on the virus envelope antigens tested. The possible origin of these antibodies is discussed. Evidence for the presence of oncornavirus particles (1-13) as well as viral antigens (14) (15) (16) (17) (18) (19) (20) , RNA-dependent DNA polymerase (reverse transcriptase) (21) (22) (23) (24) (25) , and nucleic acids (22, (26) (27) (28) (29) in normal and malignant human tissues has accumulated steadily over the past few years. Another approach to search for C type virus information in humans is to screen sera from healthy individuals and from patients for antibodies reacting with tumor virus antigens. The presence of such antibodies may indicate previous viral infection.
In the absence of C type tumor virus strains of undisputable human origin, we made use of the observation that comparative analysis of C type animal viruses generally revealed close immunological and biochemical similarities between virus strains isolated from the same or evolutionary related species. It could, therefore, be assumed that the yet putative human C type viruses may share antigenic determinants and nucleic acid homologies with virus strains of higher primates-i.e., monkeys and apes. For this reason we have used structural proteins of C type viruses from monkeys to survey human sera for the presence of antibodies reacting with C type viral antigens.
Our previous investigations revealed the presence of antibodies in the majority of human sera that react with antigens in preparations of C type primate viruses . These data are in agreement with related findings from some laboratories (34) (35) (36) , but contradict reports from several others that were unable to demonstrate human antibodies reacting with RNA tumor virus antigens (37) (38) (39) . The reasons for these discrepancies remain unclear at present, but they may have been caused by using different human sera, different immunological detection techniques, virus antigens prepared by different procedures, and different interpretation of the data (discussed in refs. 30 and 31) .
To resolve these discrepancies, both improvement of the immunological detection techniques and the use of viral antigens purified to homogeneity (40, 41) normal human sera that precipitate soluble, purified virus envelope glycoproteins from the complex of simian sarcoma virus (SSV) and simian sarcoma-associated virus (SSAV) and from Friend leukemia virus (FLV).
MATERIALS AND METHODS Preparation of Virus Antigens. SSV(SSAV) is a virus complex consisting of the replication-defective SSV and the helper virus SSAV, which provides the major envelope glycoprotein, gp7O. Similarly, FLV consists of the spleen focus-forming virus and its helper virus, the lymphoid leukosis virus, which provides the gp7l FLV. For the sake of brevity, the major virus glycoproteins will be designated as gp70 SSV(SSAV) and gp7l FLV. SSV(SSAV) and FLV were grown in HF SSV/JU suspension marmoset cells (42) and Eveline STU-mouse suspension cells (43) , respectively, by W. Schafer, V. Moennig, and H.-J. Thiel (Max-Planck-Institute fur Virusforschung, Tfibingen, West Germany). The same colleagues also purified the corresponding virus envelope glycoproteins (40, 41) . The purification of the major degradation product of gp7O SSV(SSAV), the gp45 SSV(SSAV), by H.-J. Thiel and W. Schafer will be published elsewhere (44) .
lodination of Virus Antigens. The procedure followed has been described previously (31) . One millicurie (1 curie = 3.7 X 1010 becquerels) of Na125I (Radiochemical Centre, Amersham, United Kingdom) was added to as little as 10,ug of purified virus glycoprotein and the iodination was started by the addition of chloramine-T (1 ug/Mg of virus glycoprotein). After 2 min, the reaction was stopped with sodium metabisulfite (3 Mg/,Mg of virus glycoprotein). The 125I-labeled virus glycoproteins were immediately separated from free iodine on small (10 cm3) Sephadex G-25 columns. Under these conditions, the specific radioactivity of the labeled virus glycoproteins was in the range of 2-5 X 103 cpm/ng of protein as measured in an Intertechnique gamma scintillation counter (model CG30; approximate counting efficiency for 125I 30%). We deliberately refrained from labeling virus proteins to higher specific radioactivity because this usually resulted in loss of antigenicity. gp45 SSV(SSAV) represented an exception to this rule because it could be labeled to much higher specific radioactivity (>3 X 104 cpm/ng of protein) without loss of antigenicity.
Radioimmunoprecipitation Assay (RIA). Our modification of the RIA, which detects low-as well as high-affinity IgG antibodies, has been described in detail (30) (31) (32) Second antibody was produced by immunizing rabbits with purified goat IgG and goats with human and rabbit IgG, according to published procedures (46) .
RESULTS
In earlier experiments (30) using detergent-disrupted C type viruses as antigens, human sera with high, intermediate, and no antibody titers were found. These as well as additional sera were tested again once virus antigens purified to homogeneity became available (40, 41) . Fig. 1 illustrates the precipitating activities for 10 ,ul of sera at increasing dilutions. The goat hyperimmune sera precipitated practically all of the input viral antigen, whereas the various human sera reach only certain plateaus of maximal precipitation that cannot be increased by adding more antibody. This "plateau phenomenon" has been observed with almost all positive human sera.
It can further be seen from Fig. 1 that those sera reacting well with gp7O SSV(SSAV) also react well with gp7l FLV, whereas sera without reactivity reacted with neither of the virus antigens. This again is a general observation and indicates that human antibodies may be directed against common interspecies-specific determinants on the different virus glycoproteins.
In competition RIAs, excess unlabeled gp7O SSV(SSAV) and gp7l FLV, respectively, completely inhibited the precipitation of the iodinated homologous virus antigen preparation (47) .
In heterologous competition RIAs, an interesting observation emerged. Excess unlabeled gp7O of SSV(SSAV) was able to completely block the precipitation of iodinated gp7l FLV ( Fig.  2A) , whereas unlabeled gp7l FLV could never completely block the precipitation of iodinated gp7O SSV(SSAV) (Fig. 2B) . This implies the presence of human antibodies that recognize antigenic determinants on gp7O SSV(SSAV) that are not present on gp7l FLV.
For negative control purposes, avian C type tumor virus antigens were also employed in the RIA competition assays described above. These antigens were unable to prevent binding of radioactive antigens in homologous or heterologous competition RIAs, confirming similar negative data obtained previously (30) . Likewise, human sera nonreactive in direct RIA titrations remained negative when unlabeled homologous or heterologous virus antigens were added.
The inability of most human sera to precipitate all of the input gp7O SSV(SSAV) antigen, no matter how little antigen was offered (Fig. 1) , needed further study. The most likely explanation was that partial degradation of the antigen preparation had led to degraded molecules with altered-antigenicity. To elucidate the structural integrity of virus antigens after the long incubation periods encountered during RIAs, immunoprecipitates were subjected to sodium dodecyl sulfate/ polyacrylamide gel electrophoresis followed by autoradiograMedical Sciences: Kurth and phy. The autoradiography of 125I-gp70 SSV(SSAV) precipitated by human and by normal and hyperimmune animal control sera is shown in Fig. 3 SSV(SSAV). Symbols as in Fig. 1 , except for V, NHS 30. ration had been degraded (44) . Similar to murine leukemia virus (48) , the major degradation product is a gp45 with a broad band characteristic for glycoproteins (44 Schafer (44) ]. Human sera that reacted with gp70 SSV(SSAV) also reacted with gp45 SSV(SSAV) (Fig. 4) , although, as with gp7O SSV(SSAV) (Fig. 5) , only a portion of the input gp45 SSV(SSAV) could be precipitated (Fig. 6) (Fig. 7) under conditions of antibody excess. There was no synergistic effect when individual human sera were pooled-i.e., the precipitating activity of the pooled sera was approximately equal to the titer of the highest serum in the pool. This indicates that human sera recognize the same and not different antigenic determinants on the viral glycoproteins. 
DISCUSSION
Human sera, which previously were shown to react with individual virus polypeptides in suspensions of detergent-treated virus particles, have now been tested against virus polypeptides purified to homogeneity. When detergent-treated iodinated virus particles had been used as antigens, it was noted that positive human sera reacted preferentially with the virus envelope glycoprotein gp70 of SSV(SSAV) and much less often with the p28 and p15 virus structural proteins (30) (31) (32) . The absolute amounts of viral antigens precipitable by given quantities of human sera were somewhat lower when purified viral antigens were used as compared to antigens in detergent-disrupted virus preparations (30) . These quantitative differences may be due either to the possibility that, in preparations of detergent-disrupted iodinated virus, residual virus polypeptides remained linked or to the fact that purified virus antigens are more susceptible to degradation, which in turn may both prevent antibody binding and lower binding avidity and thus resistance to sediment washing procedures in the RIAs.
The preferential reactivity of human sera with the virus envelope gp70, shown here with purified gp70 preparations, correlates with the specificity of the major natural anti-viral antibody populations in mice and cats (49, 50) .
In this context, the following observation should be noted. There are two colleagues in different laboratories from different countries who possess exceptionally high anti-gp7O SSV(SSAV) antibody titers and are able to precipitate 100% of the input antigen (no plateau effect). For years, these colleagues have been engaged in work with SSV(SSAV). Even though no "preimmune" sera from times before their known exposure to C type viruses are available, it may be assumed that the presence of antibodies is the consequence of their continued exposure to SSV(SSAV). Interestingly, these two sera possess only very low anti-p28 SSV(SSAV) antibodies, suggesting that, when confronted with infectious C type viruses the dominant human humoral immune response is directed against virus envelope antigens.
The importance of certain modifications of the RIA for the successful detection of human antibodies reacting with C type viral antigens has previously been stressed (30) . The results obtained with purified viral antigens support the need for these modifications. The shallow slopes of many human sera titrated against viral envelope antigens (Fig. 1) bodies to gp70 SSV(SSAV) (F. Katz, M. Steward, and R. Kurth, unpublished data).
The inability of human sera to precipitate all of whatever little virus antigen was offered remained a puzzle (Figs. 1, 4 , and 5). Our original interpretation that degradation products of the gp70 SSV(SSAV) may no longer be precipitable by human antibodies was no longer valid after it was observed that the major degradation product, the gp45 SSV(SSAV), could also be recognized by human antibodies. It is very interesting that the plateau effects observed with both gp7O and gp45 SSV(SSAV) are characteristic for antibodies reacting with interspecies-specific determinants on purified C type virus antigens; for example, even hyperimmune sera prepared in goats against purified gp7l FLV are unable to completely precipitate gp70 and gp45 of SSV(SSAV) via what are by definition interspecies-specific determinants (see figure 4 in ref. 44 ). Such plateau effects could possibly be caused by the limited number of recognizable interspecies-specific determinants, which means that minor (proteolytic or glycosidic) structural alterations of both gp7O and gp45 SSV(SSAV) may render them nonprecipitable for human antibodies. This explanation is the more likely because we and others (H. W. Snyder, personal communication) observed that the quality (integrity) of the antigen probe is crucial for the detection of reactive human sera.
The limited specificity of the human antibodies may, in turn, be interpreted that it was not SSV(SSAV) that had originally induced the antibodies, but, if a virus at all, it must have been a virus with only partial antigenic similarities to SSV(SSAV)..
At this time, the question of whether viruses have induced the antibodies reacting with SSV(SSAV) antigens is impossible to decide. In an environment full of potentially related antigenic stimuli, nonviral antigens may also have been responsible for the induction of the antibodies described here. On the other hand, to our knowledge, nonviral antigens sharing specificities with C type viruses have not yet been described.
With regard to the origin and mechanism of anti-viral antibody induction, another new phenomenon deserves attention. Moroni and Schumann (51) as well as Wecker et al. (52) recently detected that mouse B and T lymphocytes stimulated under certain experimental conditions by mitogens or antigens become positive for C type virus production or gp7O expression on their cell surface. It remains to be seen whether a similar mechanism, which in turn may be responsible for anti-gp7O antibody induction, operates in humans.
We have recently screened sera from a large number of patients with malignant, auto-immune, or complement-disorders. So 
